Clinical Trials & Research
Oncology Nurse Navigators
High-Risk Cancer Genetics
See All Your Doctors in One Visit
Events & Support Groups
Fitness & Wellness
Home > Testing & Treatment > Clinical Trials & Research
Treatment options, finding physicians or seeking second opinions? Let us help you find the answers. Contact us.
Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, manage side effects of treatment, and improve quality of life.
The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.
Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 40 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.
For more information about clinical trials, contact:
Jeanne Noble, at (319) 363-2690 ext. 1 or email@example.com
or Kelli Mitchell at (319) 363-2690 ext. 2 or firstname.lastname@example.org
Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
EA1181: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
CP-13-001: Margin Probe: MarginProbe® 2.0 Data Collection Study
NSABP B-61: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen ReceptorPositive, Her2-Negative Early Breast Cancer
S0820: Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES)
A021502: Randomized Trial of Standard Chemotherapy Alone orCombined with Atezolizumab as Adjuvant Therapy for Patients with Stage IIIColon Cancer and Deficient DNA Mismatch Repair
WF-1806:Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: ARandomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
NRG-GI005: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
Second Colorectal Cancer Clinical Validation Study to Predict Recurrence using a Circulation Tumor Assay to Detect Minimal Residual Disease
NRG-GU002 - Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation FollowingRadical Prostatectomy with or Without Adjuvant Docetaxel
NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
The National Myelodysplastic Syndromes (MDS) Study
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
EAA181: Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST) **Screening trial for A081105 and E4512**
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO - **Must be enrolled on screening trial A151216**
Ph III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Vs. Placebo for Pts w/ Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **Must be enrolled on screening trial A151216**
EA5163: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with ImmunobiomarkerSIGNature-Driven Analysis
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
S1800D: A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
EA6174: STAMP: SurgicallyTreated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCI 10323: Cancer Moonshot Biobank Research Protocol
A021602: Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients withAdvanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
A221602: Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC):A Phase III Randomized, Double Blind, Placebo-Controlled Trial
WF-1804CD: Automated Heart-Health Assessment for Cancer Survivors – Assessing Effectiveness and Implementation of an HER Tool to Assess Heart Health among Survivors ( AH-HA)
S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
EAQ202: Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
A222004: A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Please note: Participation in clinical trials require that participants meet very specific eligibility criteria. Please check with your physician to see if you may be eligible. This website is periodically updated to list studies currently available. Please speak with your doctor to inquire if a particular clinical trial is currently enrolling patients.
Clinical Trials Matching Service is a free, confidential program that helps patients, their families and healthcare professionals find cancer clinical trials most appropriate to a specific patient, taking their medical and personal history in consideration. For more information, call 1-800-303-5691 or visit http://cancer.org/clinicaltrials.
The National Cancer Institute (NCI) offers a clinical trials search feature along with patient education on clinical trials. For more information, go to http://www.cancer.gov/clinicaltrials.